Controlling Oral Malodor by ClōSYS® Oral Rinse

NCT ID: NCT03160560

Last Updated: 2021-01-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Study is to assess the efficacy of two ClōSYS Oral Rinse products in human subjects in controlling oral malodor in partial fulfillment of the requirements for American Dental Association's (ADA) requirement for obtaining ADA Seal for malodor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design:

The products used in the study are: ClōSYS Alcohol-Free Oral Rinse (also referred as ClōSYS Unflavored Oral Rinse) and ClōSYS justRIGHT MILD MINT Oral Rinse (also referred as ClōSYS Flavored Oral Rinse or Gentle Mint Flavored Oral Rinse). This is an in-vivo, eight-week, a single-center, randomized, double-blind (subject/investigator), 2-way cross-over design clinical study. There are two independent groups. Each subject of each group gets crossed over to the other sub-group within a same group after the washout period. Each group has their own control group. In the first phase, 25 subjects (50%) of each group are randomly assigned to the active group; the other 25 subjects are assigned to the control group. In the second phase, the participants will be crossed over within sub-group assignment. The Study enrolled 100 subjects, aged 21 to 65 years, with a slight to strong intrinsic oral malodor, as determined by a panel of trained odor judges calibrated and standardized using a range of standard odorants sufficient to reflect the different patterns of nose receptors.

Study Plan:

Subjects will receive verbal and written oral hygiene instructions, and either one bottle (16 oz. each) of ClōSYS Unflavored Oral Rinse, ClōSYS Flavored Oral Rinse- or Placebo Oral Rinse each week. Subjects will also receive measuring cups for dispensing the rinse and a diary log for recording usage (the Oral Hygiene Kit) for use during the treatment. After a 2-week wash out period, each subject will receive another bottle of oral rinse according to their group assignment.

Subjects will be instructed to rinse twice a day, each in the morning and in the evening, with 15 mL mouth rinse for 30 seconds. They will note in their patient's log the date and time of rinsing.

Subjects will be instructed to continue with their normal oral hygiene practices, including tooth brushing but omitting any use of oral rinses or mouthwashes except for the Study materials. The subjects also will be instructed not to use other non-study related products such as breath mints, lozenge, gums, etc. as well as refraining from elective dental procedures during the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Malodor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test-Flavored Rinse

CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.

Group Type ACTIVE_COMPARATOR

ClōSYS® Flavored Rinse

Intervention Type DRUG

Subjects in Test group will receive ClōSYS® Flavored Rinse.

Placebo

CloSYS Oral Rinse product (no chlorine dioxide)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Subjects in Placebo group will receive Placebo Rinse.

Test-Unflavored Rinse

CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.

Group Type ACTIVE_COMPARATOR

ClōSYS® Unflavored Rinse

Intervention Type DRUG

Subjects in Test group will receive ClōSYS® Unflavored Rinse.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ClōSYS® Unflavored Rinse

Subjects in Test group will receive ClōSYS® Unflavored Rinse.

Intervention Type DRUG

ClōSYS® Flavored Rinse

Subjects in Test group will receive ClōSYS® Flavored Rinse.

Intervention Type DRUG

Placebo

Subjects in Placebo group will receive Placebo Rinse.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mouth rinse Mouth rinse

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completion of the Informed Consent.
* Must be able to follow verbal/written instructions.
* Between 21 to 65 years of age, male or female.
* Has normal oral interior cheek wall tissues.
* In good general health.
* Should not have any severe or debilitating disease that may impede participation.
* Average organoleptic intensity rating of at \>2.6 but \<4.5 on an intensity scale of 0-5.

Exclusion Criteria

* Pregnant or nursing.
* Diagnosis of Xerostomia, including medication induced Xerostomia.
* Oral or extraoral piercing that interferes with the clinical assessments in the mouth.
* Fixed or removable oral appliance.
* Advanced periodontal disease or excessive gingival recession.
* Known allergy or sensitivity to study products.
* Unwilling to abstain from all oral hygiene products other than those prescribed for the study.
* Heavy deposits of calculus, either supragingival and/or subgingival.
* History of severe transmittable infectious disease e.g. hepatitis, HIV, tuberculosis.
* Medical or dental condition that would be unduly affected by participation in this study.
* Any other condition that may interfere with the study.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Loma Linda University

OTHER

Sponsor Role collaborator

Rowpar Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yiming Li, DDS MSD PhD

Role: PRINCIPAL_INVESTIGATOR

Center for Dental Research, Loma Linda University School of Dentistry

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LLUSD-RPR-Malodor-ADA-2016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Experimental Mouthwashes
NCT05121909 COMPLETED PHASE4
Clinical Study on Malodor
NCT06300905 COMPLETED PHASE3
Dose-Response Study of Iocide Oral Rinse
NCT01103102 COMPLETED PHASE2